Shattuck Labs, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Taylor H. Schreiber
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 West 5th Street Austin TX United States of America 78701
- IPO Date
- Oct 9, 2020
- CIK
- 0001680367
- Website
- shattucklabs.com
- Similar Companies
- Business
- Shattuck Labs, Inc. Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company that develops novel antibodies targeting tumor necrosis factor (TNF) receptors for the treatment of inflammatory and immune-mediated diseases, including inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis. The company offers a pipeline centered on death receptor 3 (DR3) antagonists, with lead candidate SL-325, a potentially first-in-class monoclonal antibody designed for high-affinity binding, epitope specificity, and Fc-silencing to achieve complete blockade of the clinically validated TL1A/DR3 pathway; SL-425, an extended half-life DR3 antagonist advancing through IND-enabling studies for IBD; and preclinical bispecific antibodies combining DR3 with undisclosed targets for broader autoimmune indications. Founded in 2016 and headquartered in Austin, Texas, with additional operations in Durham, North Carolina, Shattuck Labs focuses on protein engineering expertise to address unmet needs in immunology and inflammation through specialized therapeutics that modulate immune responses on key cell types driving disease pathology. In August 2025, the company completed a $103 million private placement financing led by OrbiMed Advisors, with participation from other institutional investors, extending its cash runway into 2029 to support advancement of SL-325 through Phase 1 trials in healthy volunteers—following FDA clearance of its IND application—and into upcoming placebo-controlled Phase 2 studies in IBD patients; this transaction coincided with a strategic repositioning as an immunology-focused organization, including Board refreshments with new directors Daniel Baker, M.D., and Mona Ashiya, Ph.D., alongside the exit of four prior members to streamline governance for pipeline execution.
Company News
Comparing Shattuck Labs (NASDAQ:STTK) & Exicure (NASDAQ:XCUR)
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
Shattuck Labs (NASDAQ:STTK) Stock Falls 5.3% – Should You Sell?
Shattuck Labs (NASDAQ:STTK) Shares Climb 11.9% – Here’s Why
Comparing MDxHealth (NASDAQ:MDXH) & Shattuck Labs (NASDAQ:STTK)
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
3,750,000 Shares in Shattuck Labs, Inc. $STTK Purchased by Frazier Life Sciences Management L.P.
BlackRock Inc. Invests $27.32 Million in Shattuck Labs, Inc. $STTK
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
Shattuck Labs: A Receptor-Side Bet On The TL1A Boom
What Shattuck Labs Stock Topped the Market on Monday
Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?
Geron (NASDAQ:GERN) and Shattuck Labs (NASDAQ:STTK) Head to Head Comparison
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday
This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Here Are Friday’s Top Wall Street Analyst Research Calls: Albertsons, Blue Owl Capital, Cleveland-Cliffs, Chime Financial, Digital Realty, Dover, PayPal Holdings, SpaceX, and More
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $11.00 Average PT from Brokerages
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
Shattuck Labs, Inc. Announces Proposed Public Offering